Wockhardt shares hit 10% upper circuit after antibiotic Zaynich achieves 96% efficacy in Phase III clinical trial

Share it

Wockhardt Share Price | Zaynich could play a key role in treating patients suffering from complicated urinary tract infections caused by multidrug-resistant (MDR) or extensively drug-resistant (XDR)  pathogens such as Enterobacterales and Pseudomonas aeruginosa.

Leave a Comment

Your email address will not be published. Required fields are marked *